26 results on '"Romagne, Francois"'
Search Results
2. Natural Killer Cell Acceptance of H-2 Mismatch Bone Marrow Grafts in Transgenic Mice Expressing HLA-Cw3 Specific Killer Cell Inhibitory Receptor (CD158b)
3. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
4. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
5. Genetic and Antibody-Mediated Reprogramming of Natural Killer Cell Missing-Self Recognition in Vivo
6. Identification, Activation, and Selective in vivo Ablation of Mouse NK Cells via NKp46
7. Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells
8. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity
9. Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors
10. Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding
11. Pan-KIR2DL NK-receptor antibodies and their use in diagnostik and therapy
12. Compositions and methods for treating proliferative disorders
13. ANTIBODIES BINDING TO RECEPTORS KIR2DL1, -2, 3 BUT NOT KIR2DS4 AND THEIR THERAPEUTIC USE
14. COMPOSITIONS AND METHODS FOR TREATING PROLIFERATIVE DISORDERS SUCH AS NK-TYPE LDGL
15. Anti-KIR Antibody Enhancement Of Anti-Lymphoma Activity Of Natural Killer Cells As Monotherapy and In Combination With Anti-CD20 Antibodies
16. Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/IPH2102) in a preclinical xenograft tumor model
17. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
18. Natural Killer Cells Recovery After Consolidation Chemotherapy in Elderly Patients with Acute Myeloid Leukemia (AML)
19. A Phase I Study of the Anti-Natural Killer Inhibitory Receptor (KIR) Monoclonal Antibody (1-7F9, IPH2101) in Elderly Patients with Acute Myeloid Leukemia (AML): Clinical and Immunological Effects of a Single Dose Followed by Repeated Dosing.
20. IPH1101, the First Specific γδ T Cell Agonist, Shows Potent Immuno-Biological Efficacy in Low Grade Follicular Lymphoma Patients When Combined with Rituximab: Results From a Phase II Study.
21. IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody, and Lenalidomide Combine to Enhance the Natural Killer (NK) Cell Versus Multiple Myeloma (MM) Effect.
22. Characterization of Early Natural Killer Cell Reconstitution Following Autologous Transplantation in Multiple Myeloma.
23. Long Lasting Alteration of Natural Killer Cells Post-Chemotherapy in Elderly Patients with Acute Myeloid Leukemia (AML).
24. Anti-KIR (1-7F9): A Fully Human Monoclonal Antibody (mAb) That Blocks KIR2DL1, −2 and −3, Promoting Natural Killer (NK) Cell-Mediated Lysis of Tumor Cells In Vitro and In Vivo.
25. Mechanism of Actions of Non Peptide Antigens Activating Human Vγ9 / Vδ2 T Lymphocytes and their Potential Use for Immunointervention
26. Prevention of autoimmune attack by targeting specific T-cell receptors in a severe combined immunodeficiency mouse model of myasthenia gravis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.